FINWIRES · TerminalLIVE
FINWIRES

Sensata Technologies, Subsidiaries Raise Maximum Amount for Senior Note Tender Offers to $400 Million

By

Sensata Technologies (ST) and its subsidiaries Sensata Technologies BV, or STBV, and Sensata Technologies Inc., or STI, have increased the maximum tender offer amount for its cash tender offers for three series of notes to $400 million from $350 million, they said Monday.

The note series are STBV's 4.000% senior notes due 2029, STI's 4.375% senior notes due 2030, and STBV's 5.875% senior notes due 2030.

At the early tender deadline of May 29, the tenders of STBV's 2029 notes amounted to around $553.6 million, exceeding the maximum tender offer amount. The subsidiary expects to accept for purchase STBV 2029 notes up to the maximum of $400 million, as the series had the highest level of priority as stipulated in the purchase offer.

The purchase of the STBV 2029 notes will be prorated in accordance with the terms of the applicable tender offer at a rate of more than 69%, and STBV expects to make payments on the early settlement date on Tuesday, according to the statement.

Price: $49.20, Change: $-0.20, Percent Change: -0.40%

Related Articles

Wire

Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology

Anixa Biosciences (ANIX) said Monday that the Canadian Intellectual Property Office has issued a notice of allowance for a patent covering the company's ovarian cancer vaccine technology.The patent, exclusively licensed from Cleveland Clinic, includes methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Mullerian hormone receptor 2 polypeptide, the company said.Price: $2.72, Change: $+0.02, Percent Change: +0.74%

$ANIX
Wire

Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches

Oncolytics Biotech (ONCY) said Monday that initial results from a preclinical study assessing pelareorep plus RAS inhibitor modalities in a solid tumor model showed evidence of the combination's greater anti-tumor activity than with the individual approaches alone.The company said that, based on the results, it is planning further studies in models of pancreatic ductal adenocarcinoma and colorectal cancer to further assess the combinations' anti-tumor and immune effects.Full results from the initial preclinical studies are slated to be presented in the fall or winter of this year, Oncolytics said.The company's shares were up more than 8% in Monday premarket trading.

$ONCY
Wire

Susquehanna Adjusts Price Target on MGM Resorts International to $50 From $45, Maintains Positive Rating

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $45.26, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $48.57, Change: $+4.90, Percent Change: +11.22%

$MGM